Anzeige
Mehr »
Login
Montag, 13.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: Heftige Kursexplosion am Montag?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Übersicht Suchergebnisse zum Thema ESPERION

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
FrEsperion Therapeutics, Inc.: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)50ANN ARBOR, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 8, 2024, the Company granted 16 new employees 62,300 restricted stock units (RSUs) under Esperion's...
► Artikel lesen
MiEsperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues8
DiEarnings call: Esperion reveals robust Q1 growth, FDA approval boosts7
DiHeart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars3
DiEsperion Therapeutics Inc reports results for the quarter ended in March - Earnings Summary3
DiEsperion Therapeutics, Inc. - 10-Q, Quarterly Report2
DiWhy Is Esperion Therapeutics (ESPR) Stock Up 13% Today?9
DiPre-market Movers: reAlpha Tech, GreenPower Motor, Esperion Therapeutics, FibroGen, Holdco Nuvo Group D.G333OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.40 A.M. ET).In the Green reAlpha Tech Corp. (AIRE) is up over 50% at $1.29. Esperion...
► Artikel lesen
DiEsperion Therapeutics, Inc. - 8-K, Current Report2
DiEsperion Soars on Q1 Earnings Beat, Revenue Surge10
DiEsperion Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlook9
DiEsperion Therapeutics, Inc.: Esperion Reports First Quarter 2024 Financial Results64- Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally - - Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million - - Q1 Retail Prescription Equivalents Grew 43%...
► Artikel lesen
06.05.Esperion Therapeutics Q1 2024 Earnings Preview5
29.04.Esperion Therapeutics, Inc.: Esperion to Participate in Upcoming May Investor Conferences5
08.04.Esperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groups15
08.04.Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket7
07.04.Esperion Therapeutics, Inc.: Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity126- Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo - - NEXLETOL Demonstrated Clinical Benefit in Historically...
► Artikel lesen
01.04.Esperion Therapeutics, Inc.: Esperion to Ring Nasdaq Opening Bell Today, April 1, 20247
26.03.Esperion Therapeutics, Inc.: Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference6
25.03.Esperion Therapeutics, Inc.: Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.242
Seite:  Weiter >>